Samsung BioLogics IPO Price, Capital Investment Plan & Valuation Issue
In a regulatory filing (last Friday), Samsung Biologics announced its plan to raise ₩1.23tril (US$1.12bil) of new shares. Samsung BioLogics plans...
427 Views
More Harsh Reality from Teva
U.S. healthcare industry leaders from across the spectrum of industry segments continue to downplay the near-term adoption of biosimilars in the...
335 Views
Bioepis Details Don't Support the Valuation
We are following up on our previous post on the proposed listing of Samsung BioLogics US$9 Billion Valuation Is Rarefied Air in response to...
430 Views
Another Payer Speaks Cautiously
Leading U.S. pharmacy benefits manager Express Scripts (ESRX US) held a conference call today to discuss its Q2: 2016 results. The company is the...
303 Views
Study Highlights Hurdles to U.S. Uptake of Inflectra
A new study (abstract attached) presented at the European Union League Against Rheumatism (EULAR) Conference highlights one of the main hurdles to...
286 Views